Physician profile
Cathy E Collier
NPI 1083886907
$3,424.92
in general payments reported to CMS, 2019-2025
24 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $555 · 2022: $718 · 2023: $829 · 2024: $901 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,015.32 | 2021-2025 | |
| Pfizer INC. | $297.26 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $296.70 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.23 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $195.01 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $166.48 | 2021-2025 | Eliquis |
| Boston Scientific Corporation | $152.35 | 2021-2025 | Watchman Access System, Versacross Steerable Access Solution |
| Astrazeneca Pharmaceuticals LP | $150.07 | 2021-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $117.44 | 2022-2024 | |
| Esperion Therapeutics, INC. | $115.21 | 2021-2023 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.56 | 2021-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $103.75 | 2021-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $102.29 | 2023-2025 | Onpattro |
| Amgen INC. | $81.37 | 2021-2022 | |
| Scpharmaceuticals INC. | $60.05 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $44.03 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $43.17 | 2021-2023 | Arcalyst |
| Abiomed | $34.19 | 2025 | |
| Novo Nordisk INC | $33.08 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $21.56 | 2025 | Shingrix |
| Abbott Laboratories | $20.08 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.85 | 2022 | |
| Amarin Pharma, INC. | $14.76 | 2021 | |
| Grifols USA, LLC | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.